ESC Congress 2024 — The interruption of beta blocker treatment was not non-inferior to a strategy of βB continuation.

Host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) sits down with investigator, Prof Johanne Silvain
(Pitié-Salpêtrière University Hospital, Paris, FR) to discuss key results from the AβYSS trial (NCT03498066; Assistance Publique - Hôpitaux de Paris).

The ABYSS trial aims to assess the efficacy of interrupting beta blocker (βB) therapy after six months of follow-up in patients with uncomplicated myocardial infarction (MI). The study enrolled 3700 patients and followed them for one year. The primary outcome is the occurrence of major adverse cardiovascular events (MACE).

Results did not demonstrate non-inferiority, with a 21% event rate in patients with interrupted βB therapy as compared to 19% in patients in the βB continuation group. In terms of secondary outcomes, there was no improvement in quality of life, and no significant difference in rates of MACE and heart failure between both groups.

Recorded remotely from Paris  and Hamilton, 2024.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.